Lineage Q1 2026 net loss $4.8M; cash $53.4M; new COR1 program launched

Lineage Cell Therapeutics, Inc.

2026-Q1 EPS reported -$0.03 vs consensus -$0.02 ▼ miss (-47.1%)

Net loss $4.8M ($0.02 basic/$0.03 diluted EPS) vs $4.1M loss in Q1 2025.
Revenue $1.7M (+$0.2M YoY) driven by new WDI collaboration.
Cash & marketable securities $53.4M; expected to fund ops into Q2 2028.
Launched COR1 corneal endothelial cell therapy; second OPC1 spinal cord patient dosed.
First AlloSCOPE 5D milestone achieved; Joachim Fruebis appointed founding SAB member.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Lineage Cell Therapeutics, Inc. reported financial results for the quarter ended March 31, 2026.

Period: the quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 12, 2026, Lineage Cell Therapeutics, Inc. issued a press release announcing financial results for the quarter ended March 31, 2026

View on SEC.gov

Browse all earnings releases →

Lineage Cell Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-219421

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.